The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and Paraoxonase-1 activity in type 2 diabetic male patients - PubMed (original) (raw)

The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and Paraoxonase-1 activity in type 2 diabetic male patients

Farzad Shidfar et al. J Res Med Sci. 2012 Apr.

Abstract

Background: Type 2 diabetic patients are faced with a higher risk of dyslipidemia and cardiovascular disorders. This study was undertaken to assess the effect of consumption of 1 cup cranberry juice by type 2 diabetic patients on serum paraoxonase-1 (PON-1) activity, apoA-1, apoB, glucose, and Lp(a).

Methods: In a double-blind randomized clinical trial, 58 type 2 diabetic male patients were randomly divided to receive 1 cup cranberry juice (CJ) or placebo drink daily for 12 weeks. Fasting blood were obtained at beginning and at the end of study (12(th) week). Serum glucose and PON-1 activity were measured by enzymatic and colorimetric methods, respectively. ApoB, apoA-I, and Lp(a) were determined immunoturbidimetrically. The data were analyzed by SPSS version 16.

Results: There were significant decrease in serum glucose and apoB (P>0.05 and P>0.01, respectively) and significant increase in serum apoA-1 and PON-1 activity (P>0.05 and P<0.01, respectively) at the end of study in CJ group compared with control group. In CJ group at the end of study, there were significant decrease in serum glucose and apoB (P<0.01 and P<0.01, respectively) and significant increase in serum apo A-1 and PON-1 activity (P<0.01 and P<0.01, respectively) compared with initial values. In CJ group, there was no significant change in Lp(a) at the end of study compared with initial values and also compared with control group.

Conclusion: 1 cup CJ for 12 weeks is effective in reducing serum glucose and apoB and increasing apoA-1 and PON-1 activity, so may have favorite effects on reducing CVD risk factors in type 2 diabetic male patients.

Keywords: Apo B; Lp(a); apoA-1; cranberry; glucose; paraoxonase-1; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

Cited by

References

    1. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type2 diabetes as coronary heart disease equivalent: Results from 7.6 year follow up in a middle east population. Cardiovasc Diabetol. 2010;9:84. - PMC - PubMed
    1. Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: Results from a six-year cohort study in Iran. BMC Public Health. 2009;9:186. - PMC - PubMed
    1. Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH. Carotid intima- media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle- aged patients with Type2 diabetes. Diabet Med. 2009;26:384–90. - PubMed
    1. Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2004;28:180–2. - PubMed
    1. Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity and atherogenic dyslipoproteinemia in women compared with men. Diabetes. 2008;57:3289–96. - PMC - PubMed

LinkOut - more resources